LOTRISONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LOTRISONE (LOTRISONE).
Lotrisone combines betamethasone dipropionate, a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, and clotrimazole, an imidazole antifungal that inhibits CYP51 (lanosterol 14alpha-demethylase), disrupting ergosterol synthesis and fungal cell membrane integrity.
| Metabolism | Clotrimazole is primarily metabolized in the liver via oxidation and glucuronidation; betamethasone is metabolized in the liver via CYP3A4. |
| Excretion | Clotrimazole: <0.5% of dose excreted unchanged in urine; betamethasone dipropionate: primarily renal (<5% unchanged) and biliary/fecal (35-50% as metabolites). |
| Half-life | Clotrimazole: 3.5-6 hours (topical, minimal systemic absorption); betamethasone dipropionate: approximately 4-6 hours for betamethasone after hydrolysis. |
| Protein binding | Clotrimazole: 90-95% bound to plasma proteins; betamethasone: approximately 64% bound (primarily to albumin and corticosteroid-binding globulin). |
| Volume of Distribution | Clotrimazole: negligible systemic Vd due to minimal absorption; betamethasone: 1.4 L/kg (large distribution, high tissue penetration). |
| Bioavailability | Topical: minimal systemic absorption (clotrimazole <0.5%, betamethasone dipropionate <5% of dose); not formulated for oral use. |
| Onset of Action | Topical: clinical improvement often noted within 1 week of twice-daily application. |
| Duration of Action | Topical: applied twice daily; clinical cure rates high after 2 weeks of treatment; duration limited by application schedule. |
| Molecular Weight | Clotrimazole: 344.84 Da; Betamethasone dipropionate: 504.59 Da |
Apply a thin film to affected skin areas twice daily, morning and evening, for 2 weeks.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment based on Child-Pugh score. |
| Pediatric use | Apply a thin film to affected areas twice daily for 2 weeks. Not recommended for children under 2 years of age. Safety and efficacy in pediatric patients have not been established beyond 2 weeks of use. |
| Geriatric use | Use with caution due to increased risk of skin atrophy and systemic absorption. Limit treatment duration to 2 weeks. |
| 1st trimester | Topical use during the first trimester is generally avoided unless potential benefits outweigh risks; limited human data, but systemic absorption is low with short-term use. |
| 2nd trimester | Use with caution; short-term application over small areas is considered relatively safe due to minimal systemic absorption. |
| 3rd trimester | Use with caution; avoid prolonged use over large areas to prevent potential fetal adrenal suppression. |
Clinical note
Comprehensive clinical and safety monograph for LOTRISONE (LOTRISONE).
| Placental transfer | Clotrimazole: minimal; betamethasone: crosses placenta but topical use results in low systemic levels. |
| Breastfeeding | Topical application to small areas with intact skin is unlikely to result in significant systemic absorption; avoid application to breast area to prevent infant ingestion. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to clotrimazole, betamethasone, or any component of the formulationViral skin infections (e.g., herpes simplex, varicella zoster)Fungal nail infections (onychomycosis)Perioral dermatitisRosacea
| Precautions | Topical corticosteroids may cause reversible HPA axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients., Systemic absorption may be increased with use on large surface areas, prolonged use, occlusive dressings, or in pediatric patients., Local adverse reactions include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria., Concomitant skin infections should be treated with appropriate antimicrobial therapy. |
| Food/Dietary | No clinically significant food interactions. Avoid grapefruit juice if taking oral corticosteroids concurrently, though topical use has minimal systemic absorption. |
Loading safety data…
| Lactation Rating | L3: Limited data; probably compatible with cautious use |
| Teratogenic Risk | Lotrisone (clotrimazole/betamethasone dipropionate) is a topical corticosteroid/antifungal combination. Systemic absorption is minimal after topical application. Animal studies with topical corticosteroids have shown teratogenicity, but no controlled human data exist. The risk is considered low with proper use, especially in the first trimester. In the second and third trimesters, avoid prolonged or widespread use. Corticosteroids may cause intrauterine growth restriction if significant systemic absorption occurs. Overall, fetal risk is low with limited cutaneous application. |
| Fetal Monitoring | No specific routine fetal monitoring required for typical use. For prolonged or widespread use (especially of high-potency corticosteroid component), consider monitoring for signs of maternal adrenal suppression, fetal growth restriction, and preterm labor. Use intermittent fetal monitoring if prolonged therapy on large surface areas is necessary. Assess maternal blood pressure and blood glucose if significant systemic absorption suspected. |
| Fertility Effects | No known adverse effects on male or female fertility from topical application of Lotrisone. Systemic corticosteroids may affect ovulation or sperm parameters at high doses, but topical use does not produce such levels. No specific fertility monitoring is required. |
| Clinical Pearls | Lotrisone (clotrimazole/betamethasone dipropionate) is a combination antifungal and corticosteroid. Avoid use in diaper dermatitis due to increased absorption. Limit treatment to 2 weeks; prolonged use can cause skin atrophy, striae, or systemic corticosteroid effects. Not for ophthalmic, oral, or intravaginal use. May mask fungal infection; discontinue if no improvement in 1 week. |
| Patient Advice | Apply a thin film to affected skin twice daily (morning and evening). · Do not use for more than 2 weeks unless directed by your doctor. · Avoid use on the face, groin, or armpits unless specifically instructed. · Do not cover the treated area with bandages or dressings unless told to do so. · Wash hands after applying, unless treating the hands. · Inform your doctor if symptoms persist or worsen after 1 week. · Do not use for diaper rash or on broken skin. · Keep away from eyes, mouth, and vaginal area. |